153 related articles for article (PubMed ID: 26081759)
1. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors.
Liu B; Yuan X; Xu B; Zhang H; Li R; Wang X; Ge Z; Li R
Eur J Med Chem; 2019 May; 170():1-15. PubMed ID: 30878825
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
[TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of a novel class of dithiocarbamic acid esters as anticancer agent.
Hou X; Ge Z; Wang T; Guo W; Wu J; Cui J; Lai C; Li R
Arch Pharm (Weinheim); 2011 May; 344(5):320-32. PubMed ID: 21509804
[TBL] [Abstract][Full Text] [Related]
9. Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis.
Shan S; Shi J; Yang P; Jia B; Wu H; Zhang X; Li Z
J Agric Food Chem; 2017 Sep; 65(37):8136-8144. PubMed ID: 28829588
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
[TBL] [Abstract][Full Text] [Related]
12. 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2.
Yoon YJ; Kim YH; Jin Y; Chi SW; Moon JH; Han DC; Kwon BM
Cancer Lett; 2018 Oct; 434():42-55. PubMed ID: 30009856
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity.
Baviskar AT; Banerjee UC; Gupta M; Singh R; Kumar S; Gupta MK; Kumar S; Raut SK; Khullar M; Singh S; Kumar R
Bioorg Med Chem; 2013 Sep; 21(18):5782-93. PubMed ID: 23920485
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and molecular modeling of 1,3,4-thiadiazol-2-amide derivatives as novel antitubulin agents.
Li YJ; Qin YJ; Makawana JA; Wang YT; Zhang YQ; Zhang YL; Yang MR; Jiang AQ; Zhu HL
Bioorg Med Chem; 2014 Aug; 22(15):4312-22. PubMed ID: 24909678
[TBL] [Abstract][Full Text] [Related]
17. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
Li RD; Zhang X; Li QY; Ge ZM; Li RT
Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
[TBL] [Abstract][Full Text] [Related]
18. Tannic acid directly targets pyruvate kinase isoenzyme M2 to attenuate colon cancer cell proliferation.
Yang P; Ding GB; Liu W; Fu R; Sajid A; Li Z
Food Funct; 2018 Nov; 9(11):5547-5559. PubMed ID: 30259036
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
